H. Castanie

1.1k total citations
7 papers, 110 citations indexed

About

H. Castanie is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, H. Castanie has authored 7 papers receiving a total of 110 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in H. Castanie's work include Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Head and Neck Cancer Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). H. Castanie is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Head and Neck Cancer Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). H. Castanie collaborates with scholars based in France, Spain and Germany. H. Castanie's co-authors include Laurent Martin, Jean Bourhis, Christian Sire, Damien Vansteene, Esma Saâda-Bouzid, Didier Cupissol, Ulrich Keilholz, Jérôme Fayette, Ricard Mesı́a and Olivier Capitain and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

H. Castanie

7 papers receiving 110 citations

Peers

H. Castanie

ONCOL

PRM

SURGE

OTORH

MB

S. Marimuthu United States

L. Bozec Le Moal France

C. Lafond France

Sophie Wildsmith United Kingdom

Wei-Han Hu China

Olivier Mauvais France

Yi‐Nuan Zhang China

Lara Carmen Iglesias Docampo Spain

A L Klochikhin Spain

Joanna Lynch United Kingdom

S. Marimuthu United States

H. Castanie

35 ×0.4

ONCOL

30 ×0.5

PRM

25 ×0.4

SURGE

32 ×0.7

OTORH

5 ×1.0

MB

Citations per year, relative to H. Castanie H. Castanie (= 1×) peers S. Marimuthu

Countries citing papers authored by H. Castanie

Since Specialization

Citations

This map shows the geographic impact of H. Castanie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Castanie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Castanie more than expected).

Fields of papers citing papers by H. Castanie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Castanie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Castanie. The network helps show where H. Castanie may publish in the future.

Co-authorship network of co-authors of H. Castanie

This figure shows the co-authorship network connecting the top 25 collaborators of H. Castanie. A scholar is included among the top collaborators of H. Castanie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Castanie. H. Castanie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Ducreux, Michel, Méher Ben Abdelghani, David Tougeron, et al.. (2024). 3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 35. S3–S3. 1 indexed citations

2.

Zaanan, Aziz, Olivier Bouché, Christelle de la Fouchardière, et al.. (2023). LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD. Annals of Oncology. 34. S1318–S1318. 8 indexed citations

3.

Delaye, Matthieu, Éric Assenat, Laëtitia Dahan, et al.. (2022). Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study.. Journal of Clinical Oncology. 40(16_suppl). 4108–4108. 5 indexed citations

4.

Boilève, Alice, Marc Hilmi, Romain Cohen, et al.. (2020). Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. European Journal of Cancer. 143. 55–63. 35 indexed citations

5.

Guigay, J., Jérôme Fayette, Ricard Mesı́a, et al.. (2020). TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 38(15_suppl). 6507–6507. 14 indexed citations

6.

Castanie, H., et al.. (2019). Skin Metastases from Ovarian Carcinoma. 4(1). 1 indexed citations

7.

Guigay, J., Jérôme Fayette, Ricard Mesı́a, et al.. (2019). TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 37(15_suppl). 6002–6002. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact